Tag: BOT
Botanix Pharmaceuticals tracks commercial dermatology path
Botanix Pharmaceuticals (ASX: BOT) has provided the market with an update on its progress in transforming into a commercial-stage dermatology company following the acquisition of its latest asset, Sof...
Botanix acquires novel medical dermatology asset to treat axillary hyperhidrosis
Botanix Pharmaceuticals (ASX: BOT) has acquired novel dermatology asset Sofpironium Bromide gel 15% for the treatment of primary axillary (underarm) hyperhidrosis, a medical condition which results in...
Botanix Pharmaceuticals receives FDA grant for antibacterial product BTX 1801
Amid the difficulties created by the COVID-19 pandemic, synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) unveiled an operational boost in the form of support from the US FDA to fast tr...
Botanix Pharmaceuticals plans new study into antimicrobial platform and BTX 1801
Synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) has unveiled the next phase of development for its cannabinoid antimicrobial platform and lead program BTX 1801.
Earlier today, Bota...
Botanix’s CBD-based product destroys superbug skin infections in another ‘world first’
In another “world first” this week, Botanix Pharmaceuticals (ASX: BOT) has revealed its antimicrobial cannabidiol (CBD)-based product BTX 1801 can treat serious skin infections including superbugs.
...
Botanix study finds CBD has anti-inflammatory and immune modulating effects on skin disease
New results from a “world-first” study by Botanix Pharmaceuticals (ASX: BOT) has identified significant anti-inflammatory and immune modulating effects from using cannabidiol (CBD) to treat skin disea...
Botanix Pharmaceuticals and University of Queensland to develop cannabidiol treatment for superbugs
Medical dermatology company Botanix Pharmaceuticals (ASX: BOT) is moving ahead with developing its BTX 1801 pipeline product, a cannabidiol-based treatment for various dermatological conditions.
BT...
Botanix Pharmaceuticals fully funded to complete phase 2 atopic dermatitis trial
Medical dermatology company Botanix Pharmaceuticals (ASX: BOT) has raised A$8 million through an oversubscribed placement to professional, institutional and sophisticated investors across Australia an...
Botanix Pharmaceuticals receives strong results amid growing dermatitis rates
Dermatology company Botanix Pharmaceuticals (ASX: BOT) has published successful results from its phase 1b patient study looking into the safety profile of its cannabidiol-based BTX 1204 transdermal ge...
Botanix receives FDA go-ahead for progressive acne treatment
Dermatology company Botanix Pharmaceuticals (ASX: BOT) has received the green light from the US Food and Drug Administration (FDA) for its BTX 1503 phase 2 clinical acne trial.
Botanix is currently...
Botanix poised to kick-off new study with CBD-based atopic dermatitis treatment
Botanix Pharmaceuticals (ASX: BOT) has now enrolled all patients required to kick-off its phase 1b atopic dermatitis study where it will test is cannabidiol-based BTX 1204 topical treatment.
The en...
Botanix’s acne treatment outperforms current ‘leading’ topical products
Botanix Pharmaceuticals’ (ASX: BOT) synthetic cannabidiol-based BTX 1503 acne treatment has performed better than “leading” topically applied acne products in reducing acne lesions during a four-week ...
Botanix Pharma’s acne product effects antibiotic-resistant acne
Medical dermatology company Botanix Pharmaceuticals (ASX: BOT) revealed trials of its synthetic cannabidiol-based acne product BTX 1503 has demonstrated antibacterial activity against acne.
In the ...
First patients enrolled for Botanix Pharmaceuticals’ dermatitis trial
Botanix Pharmaceuticals (ASX: BOT) has enrolled its first patients for its phase 1b clinical trial into its proprietary BTX 1204 treatment on atopic dermatitis sufferers.
Atopic dermatitis is a com...
Botanix Pharmaceuticals kicks-off atopic dermatitis trials
Botanix Pharmaceuticals (ASX: BOT) is full steam ahead with beginning its atopic dermatitis study in Australia after getting the green light from the Human Research Ethics Committee.
Named BTX 1204...
